The Developmental Research Program is a major focus for the SPORE because this mechanism provides a continuous flow of new ideas, projects and investigators to stimulate translational breast cancer research in the context of the SPORE. It provides the opportunity to encourage and facilitate the development of new directions, methodologies, and collaboration. It is also a major vehicle to allow the SPORE broad access to investigators at The Johns Hopkins University and Howard University in Washington, D.C. Its importance is signaled by the fact that about 8% of the direct costs of the SPORE are invested in the Developmental Research Program. A two-tiered review and approval process for pilot projects is used analogous to that employed by the National Institutes of Health. A Scientific Review Committee led by Bert Vogelstein, M.D. reviews proposals for their scientific merit. The Breast Cancer SPORE Steering Committee makes final funding decisions using the scientific review from Dr. Vogelstein's review committee and programmatic priorities to guide its selections. The SPORE Principal Investigator, Dr. Davidson, serves as administrative coordinator with able assistance from the SPORE coordinator, Cindy Morin.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA088843-09
Application #
7902237
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-30
Budget End
2010-09-29
Support Year
9
Fiscal Year
2009
Total Cost
$173,824
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Sadik, Helen; Korangath, Preethi; Nguyen, Nguyen K et al. (2016) HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Res 76:4443-56
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93

Showing the most recent 10 out of 282 publications